Prevalence and Specificity of LKB1 Genetic Alterations in Lung Cancers

Overview

Journal Oncogene

Specialties Molecular Biology
Oncology

Date 2007 Mar 27

PMID 17384680

Citations 140

Authors

S Matsumoto

R Iwakawa

K Takahashi

T Kohno

Y Nakanishi

Y Matsuno

K Suzuki

M Nakamoto

E Shimizu

J D Minna

J Yokota

Affiliations

Soon will be listed here.

Abstract

Germline LKB1 mutations cause Peutz-Jeghers syndrome, a hereditary disorder that predisposes to gastrointestinal hamartomatous polyposis and several types of malignant tumors. Somatic LKB1 alterations are rare in sporadic cancers, however, a few reports showed the presence of somatic alterations in a considerable fraction of lung cancers. To determine the prevalence and the specificity of LKB1 alterations in lung cancers, we examined a large number of lung cancer cell lines and lung adenocarcinoma (AdC) specimens for the alterations. LKB1 genetic alterations were frequently detected in the cell lines (21/70, 30%), especially in non-small cell lung cancers (NSCLCs) (20/51, 39%), and were significantly more frequent in cell lines with KRAS mutations. Point mutations were detected only in AdCs and large cell carcinomas, whereas homozygous deletions were detected in all histological types of lung cancer. Among lung AdC specimens, LKB1 mutations were found in seven (8%) of 91 male smokers but in none of 64 females and/or nonsmokers, and were significantly more frequent in poorly differentiated tumors. The difference in the frequency of LKB1 alterations between cell lines and tumor specimens was likely to be owing to masking of deletions by the contamination of noncancerous cells in the tumor specimens. These results indicate that somatic LKB1 genetic alterations preferentially occur in a subset of poorly differentiated lung AdCs that appear to correlate with smoking males.

Citing Articles

A phase II trial of mTORC1/2 inhibition in STK11 deficient non small cell lung cancer.

Middleton G, Robbins H, Fletcher P, Savage J, Mehmi M, Summers Y NPJ Precis Oncol. 2025; 9(1):67.

PMID: 40069402 PMC: 11897347. DOI: 10.1038/s41698-025-00838-4.

The therapeutic potential of RNA m(6)A in lung cancer.

Yu J, Sun W, Zhao X, Chen Y Cell Commun Signal. 2024; 22(1):617.

PMID: 39736743 PMC: 11687105. DOI: 10.1186/s12964-024-01980-5.

Insights into targeting LKB1 in tumorigenesis.

Trelford C, Shepherd T Genes Dis. 2024; 12(2):101402.

PMID: 39735555 PMC: 11681833. DOI: 10.1016/j.gendis.2024.101402.

Role of SIK1 in tumors: Emerging players and therapeutic potentials (Review).

Zhang X, Liu J, Zuo C, Peng X, Xie J, Shu Y Oncol Rep. 2024; 52(6).

PMID: 39422046 PMC: 11544583. DOI: 10.3892/or.2024.8828.

TET2-STAT3-CXCL5 nexus promotes neutrophil lipid transfer to fuel lung adeno-to-squamous transition.

Xue Y, Chen Y, Sun S, Tong X, Chen Y, Tang S J Exp Med. 2024; 221(7).

PMID: 38805014 PMC: 11129275. DOI: 10.1084/jem.20240111.

References

Tiainen M, Vaahtomeri K, Ylikorkala A, Makela T . Growth arrest by the LKB1 tumor suppressor: induction of p21(WAF1/CIP1). Hum Mol Genet. 2002; 11(13):1497-504. DOI: 10.1093/hmg/11.13.1497. View

Sanchez-Cespedes M, Parrella P, Esteller M, Nomoto S, Trink B, Engles J . Inactivation of LKB1/STK11 is a common event in adenocarcinomas of the lung. Cancer Res. 2002; 62(13):3659-62. View

Tomizawa Y, Kohno T, Kondo H, Otsuka A, Nishioka M, Niki T . Clinicopathological significance of epigenetic inactivation of RASSF1A at 3p21.3 in stage I lung adenocarcinoma. Clin Cancer Res. 2002; 8(7):2362-8. View

Park M, Shimizu K, Nakano T, Park Y, Kohno T, Tani M . Pathogenetic and biologic significance of TP14ARF alterations in nonsmall cell lung carcinoma. Cancer Genet Cytogenet. 2003; 141(1):5-13. DOI: 10.1016/s0165-4608(02)00645-3. View

Ghaffar H, Sahin F, Sanchez-Cepedes M, Su G, Zahurak M, Sidransky D . LKB1 protein expression in the evolution of glandular neoplasia of the lung. Clin Cancer Res. 2003; 9(8):2998-3003. View

Carretero J, Medina P, Pio R, Montuenga L, Sanchez-Cespedes M . Novel and natural knockout lung cancer cell lines for the LKB1/STK11 tumor suppressor gene. Oncogene. 2004; 23(22):4037-40. DOI: 10.1038/sj.onc.1207502. View

Baas A, Smit L, Clevers H . LKB1 tumor suppressor protein: PARtaker in cell polarity. Trends Cell Biol. 2004; 14(6):312-9. DOI: 10.1016/j.tcb.2004.04.001. View

Jenne D, Reimann H, Nezu J, FRIEDEL W, Loff S, Jeschke R . Peutz-Jeghers syndrome is caused by mutations in a novel serine threonine kinase. Nat Genet. 1998; 18(1):38-43. DOI: 10.1038/ng0198-38. View

Hemminki A, Markie D, Tomlinson I, Avizienyte E, Roth S, Loukola A . A serine/threonine kinase gene defective in Peutz-Jeghers syndrome. Nature. 1998; 391(6663):184-7. DOI: 10.1038/34432. View

10.

Sanchez-Cespedes M, Ahrendt S, Piantadosi S, Rosell R, Monzo M, Wu L . Chromosomal alterations in lung adenocarcinoma from smokers and nonsmokers. Cancer Res. 2001; 61(4):1309-13. View

11.

Avizienyte E, Loukola A, Roth S, Hemminki A, Tarkkanen M, Salovaara R . LKB1 somatic mutations in sporadic tumors. Am J Pathol. 1999; 154(3):677-81. PMC: 1868601. DOI: 10.1016/S0002-9440(10)65314-X. View

12.

Guldberg P, Thor Straten P, Ahrenkiel V, Seremet T, Kirkin A, Zeuthen J . Somatic mutation of the Peutz-Jeghers syndrome gene, LKB1/STK11, in malignant melanoma. Oncogene. 1999; 18(9):1777-80. DOI: 10.1038/sj.onc.1202486. View

13.

Westerman A, Entius M, de Baar E, Boor P, Koole R, Van Velthuysen M . Peutz-Jeghers syndrome: 78-year follow-up of the original family. Lancet. 1999; 353(9160):1211-5. DOI: 10.1016/s0140-6736(98)08018-0. View

14.

Su G, Hruban R, Bansal R, Bova G, Tang D, Shekher M . Germline and somatic mutations of the STK11/LKB1 Peutz-Jeghers gene in pancreatic and biliary cancers. Am J Pathol. 1999; 154(6):1835-40. PMC: 1866632. DOI: 10.1016/S0002-9440(10)65440-5. View

15.

Hemminki A . The molecular basis and clinical aspects of Peutz-Jeghers syndrome. Cell Mol Life Sci. 1999; 55(5):735-50. PMC: 11146769. DOI: 10.1007/s000180050329. View

16.

Kosaka T, Yatabe Y, Endoh H, Kuwano H, Takahashi T, Mitsudomi T . Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res. 2004; 64(24):8919-23. DOI: 10.1158/0008-5472.CAN-04-2818. View

17.

Kishimoto M, Kohno T, Okudela K, Otsuka A, Sasaki H, Tanabe C . Mutations and deletions of the CBP gene in human lung cancer. Clin Cancer Res. 2005; 11(2 Pt 1):512-9. View

18.

Hearle N, Tomlinson I, Lim W, Murday V, Swarbrick E, Lim G . Sequence changes in predicted promoter elements of STK11/LKB1 are unlikely to contribute to Peutz-Jeghers syndrome. BMC Genomics. 2005; 6:38. PMC: 1084245. DOI: 10.1186/1471-2164-6-38. View

19.

Launonen V . Mutations in the human LKB1/STK11 gene. Hum Mutat. 2005; 26(4):291-7. DOI: 10.1002/humu.20222. View

20.

Shigematsu H, Gazdar A . Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers. Int J Cancer. 2005; 118(2):257-62. DOI: 10.1002/ijc.21496. View